53 research outputs found

    Anisotropic Superconducting Properties of Optimally Doped BaFe2_2(As0.65_{0.65}P0.35_{0.35})2_2 under Pressure

    Full text link
    Magnetic measurements on optimally doped single crystals of BaFe2_2(As1x_{1-x}Px_{x})2_2 (x0.35x\approx0.35) with magnetic fields applied along different crystallographic axes were performed under pressure, enabling the pressure evolution of coherence lengths and the anisotropy factor to be followed. Despite a decrease in the superconducting critical temperature, our studies reveal that the superconducting properties become more anisotropic under pressure. With appropriate scaling, we directly compare these properties with the values obtained for BaFe2_2(As1x_{1-x}Px_{x})2_2 as a function of phosphorus content.Comment: 5 pages, 3 figure

    Pressure-induced and Composition-induced Structural Quantum Phase Transition in the Cubic Superconductor (Sr/Ca)_3Ir_4Sn_{13}

    Full text link
    We show that the quasi-skutterudite superconductor Sr_3Ir_4Sn_{13} undergoes a structural transition from a simple cubic parent structure, the I-phase, to a superlattice variant, the I'-phase, which has a lattice parameter twice that of the high temperature phase. We argue that the superlattice distortion is associated with a charge density wave transition of the conduction electron system and demonstrate that the superlattice transition temperature T* can be suppressed to zero by combining chemical and physical pressure. This enables the first comprehensive investigation of a superlattice quantum phase transition and its interplay with superconductivity in a cubic charge density wave system.Comment: 4 figures, 5 pages (excluding supplementary material). To be published in Phys. Rev. Let

    Baseline characteristics of patients in the reduction of events with darbepoetin alfa in heart failure trial (RED-HF)

    Get PDF
    <p>Aims: This report describes the baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF) which is testing the hypothesis that anaemia correction with darbepoetin alfa will reduce the composite endpoint of death from any cause or hospital admission for worsening heart failure, and improve other outcomes.</p> <p>Methods and results: Key demographic, clinical, and laboratory findings, along with baseline treatment, are reported and compared with those of patients in other recent clinical trials in heart failure. Compared with other recent trials, RED-HF enrolled more elderly [mean age 70 (SD 11.4) years], female (41%), and black (9%) patients. RED-HF patients more often had diabetes (46%) and renal impairment (72% had an estimated glomerular filtration rate <60 mL/min/1.73 m2). Patients in RED-HF had heart failure of longer duration [5.3 (5.4) years], worse NYHA class (35% II, 63% III, and 2% IV), and more signs of congestion. Mean EF was 30% (6.8%). RED-HF patients were well treated at randomization, and pharmacological therapy at baseline was broadly similar to that of other recent trials, taking account of study-specific inclusion/exclusion criteria. Median (interquartile range) haemoglobin at baseline was 112 (106–117) g/L.</p> <p>Conclusion: The anaemic patients enrolled in RED-HF were older, moderately to markedly symptomatic, and had extensive co-morbidity.</p&gt
    corecore